Data / Form D filings / Vivex Biomedical, Inc.
Vivex Biomedical, Inc.: Form D filings
Vivex Biomedical, Inc., a biotechnology company in Atlanta, GA, filed 5 Form D notices with the SEC between 2013 and 2017. The latest, on May 11, 2017, reports $6.3 million sold of a $7 million offering to 38 investors.
Find out what Vivex Biomedical, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3200 WINDY HILL ROAD, SUITE 1650W, Atlanta, GA, 30339
- Phone
- (855) 698-4839
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2012
- Revenue range
- $25,000,001 - $100,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1581881
The full lists. Form D filings in Georgia: 1,337 rows, $66.85, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 11, 2017 | Amendment | $7,000,000 | $6,280,065 | $719,935 | 38 | Jan 24, 2017 | sec.gov |
| Jan 26, 2017 | New notice | $5,000,000 | $0 | $5,000,000 | 0 | Yet to occur | sec.gov |
| Jan 5, 2016 | New notice | $10,000,000 | $6,609,235 | $3,390,765 | 42 | Dec 23, 2015 | sec.gov |
| Sep 16, 2013 | Amendment | $7,241,400 | $7,241,400 | $0 | 51 | Jul 12, 2013 | sec.gov |
| Jul 18, 2013 | New notice | $5,500,000 | $2,180,000 | $3,320,000 | 20 | Jul 12, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Timothy Thomas Ganey, Ph.D. | Executive Officer | |
| Holly S. Mason | Executive Officer | |
| John A. McCallum | Director | |
| Barry Thomas Salzman | Director | |
| Dr. H Thomas Temple | Executive Officer | |
| James K. Price | Director | |
| Tracy S. Anderson | Executive Officer, Director | |
| J. Miguel Fernandez de Castro | Director | |
| Timothy S. Taylor | Director | |
| U. Bertram Ellis, Jr. | Director | |
| Stuart J Komenski | Executive Officer | |
| Richard E. Perlman | Director |
Other biotechnology companies in Georgia that filed recently
- Opus Medical Therapies, LLC $485,089 · Sep 22, 2026
- Airway Therapeutics, Inc. $43.5 million · Sep 9, 2026
- FEMASYS INC $30 million · Aug 20, 2026
Every Form D from the week of May 8, 2017 · All recent filings in Georgia · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Vivex Biomedical, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.